

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Diabetes-related symptoms, acute complications and management of diabetes mellitus in palliative care: a protocol for a systematic review.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028604
Article Type:	Protocol
Date Submitted by the Author:	18-Dec-2018
Complete List of Authors:	<p>Bettencourt-Silva, Rita; Centro Hospitalar Universitário São João, Department of Endocrinology, Diabetes and Metabolism; Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, University of Porto</p> <p>Aguiar, Beatriz; Unidade de Saúde de Ilha de São Miguel, Unidade de Saúde de Rabo de Peixe</p> <p>Sá-Araújo, Vânia; Instituto Português de Oncologia do Porto Francisco Gentil, Department of Palliative Care</p> <p>Barreira, Rosa; Unidade de Saúde Familiar Maresia, Unidade Local de Saúde de Matosinhos</p> <p>Guedes, Vânia; Unidade de Saúde Familiar São João do Porto, Agrupamento de Centros de Saúde (ACES) do Porto Ocidental</p> <p>Marques Ribeiro, Maria João; Centro Hospitalar Universitário São João, Department of Medical Oncology</p> <p>Carvalho, Davide ; Centro Hospitalar Universitário de São João, Department of Endocrinology, Diabetes and Metabolism; Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, University of Porto</p> <p>Östlundh, Linda; United Arab Emirates University College of Medicine and Health Sciences, National Medical Library</p> <p>Paulo, Marília Silva; United Arab Emirates University College of Medicine and Health Sciences, Institute of Public Health; Universidade Nova de Lisboa Instituto de Higiene e Medicina Tropical,</p>
Keywords:	DIABETES & ENDOCRINOLOGY, PALLIATIVE CARE, Adult palliative care < PALLIATIVE CARE, General diabetes < DIABETES & ENDOCRINOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Diabetes-related symptoms, acute complications and management of diabetes**  
4  
5 **mellitus in palliative care: a protocol for a systematic review.**  
6  
7

8  
9 Rita Bettencourt-Silva<sup>1,2,3</sup>, Beatriz Aguiar<sup>4</sup>, Vânia Sá-Araújo<sup>5</sup>, Rosa Barreira<sup>6</sup>, Vânia Guedes<sup>7</sup>,  
10 Maria João Marques Ribeiro<sup>8</sup>, Davide Carvalho<sup>1,2,3</sup>, Linda Östlundh<sup>9</sup>, Marília Silva Paulo<sup>10,11\*</sup>  
11  
12  
13

14  
15  
16 <sup>1</sup> Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São  
17 João, Porto, Portugal.  
18

19  
20 <sup>2</sup> Faculty of Medicine of University of Porto, Porto, Portugal.  
21

22 <sup>3</sup> Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.  
23

24 <sup>4</sup> Unidade de Saúde da Ilha de São Miguel, Unidade de Saúde de Rabo de Peixe, Ribeira Grande,  
25 São Miguel, Açores, Portugal.  
26

27  
28 <sup>5</sup> Department of Palliative Care, Instituto Português de Oncologia do Porto Francisco Gentil,  
29 Porto, Portugal .  
30

31  
32 <sup>6</sup> Unidade de Saúde Familiar Maresia, Unidade Local de Saúde de Matosinhos, Matosinhos,  
33 Portugal.  
34

35  
36  
37 <sup>7</sup> Unidade de Saúde Familiar São João do Porto, Agrupamento de Centros de Saúde (ACES) do  
38 Porto Ocidental, Porto, Portugal.  
39

40  
41 <sup>8</sup> Department of Medical Oncology, Centro Hospitalar Universitário de São João, Porto, Portugal.  
42

43 <sup>9</sup> National Medical Library, College of Medicine and Health Sciences, United Arab Emirates  
44 University. Al Ain, United Arab Emirates.  
45

46  
47 <sup>10</sup> Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates  
48 University. Al Ain, United Arab Emirates.  
49

50  
51 <sup>11</sup> Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade  
52 Nova de Lisboa, Lisboa, Portugal.  
53

54  
55  
56 \* Address of corresponding author:  
57

1  
2  
3 Marilia Silva Paulo

4  
5 mariliap@uaeu.ac.ae

6  
7 Institute of Public Health

8  
9 College of Medicine and Health Sciences

10  
11 United Arab Emirates University.

12  
13 PO Box: 17666, Al Ain, United Arab Emirates.

14  
15  
16  
17  
18 Word count: 1718

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

**Introduction:** Worldwide, an estimated 40 million people are in need of palliative care each year, but only 14% receive it. The incidence of diabetes mellitus (DM) in patients receiving palliative care is higher than in general population. This association is intended to grow as a result of the rising burden on DM worldwide, ageing populations and the improved overall survival time in last decades in several diseases. Recommendations for DM management in the context of palliative care are mainly based on expert opinions. There is a lack of suitable evidence base and randomized clinical trials in palliative care are scarce. The aim of our systematic review is to access the best management of DM in order to reduce important DM-related symptoms and acute complications in patients receiving palliative care.

**Methods and analysis:** The authors will study the state of the art on DM treatment and management, surveying the different approaches employed in palliative care adult patients. Sources of data will be Ovid MEDLINE, Embase, PubMed, Web of Sciences, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, CINAHL, and grey literature. Details regarding diet, oral and injectable antidiabetic drugs, insulin regimens and blood glucose monitoring strategies will be evaluated. Primary outcomes will be the presence of symptoms (polyuria, polydipsia, and polyphagia) and acute complications (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic ketoacidosis) of DM. Secondary outcomes will be hospital admission and deaths due to DM-related complications, health-related quality of life, and glyceemic control.

**Ethics and dissemination:** The systematic review methodology does not require ethical approval due to the nature of the study design. The results of the systematic review will be published in a peer-reviewed journal and publically available. It will also be disseminated electronically and in print.

**PROSPERO registration number:** CRD42018115772

**Strengths and limitations of this study:**

- The present protocol is an outline of the systematic review specificities that will guide the authors while conducting the systematic review on the diabetes-related symptoms, acute complications and management of diabetes mellitus in palliative care.
- The results of this systematic review will be strength of evidence of the different approaches used to manage diabetes mellitus in palliative care, identified from clinicians as need in the daily-care of patients with diabetes mellitus receiving palliative care.
- This systematic review will include studies of any study design because, as far as we know, this is the first systematic review on the diabetes-related symptoms and complications in palliative care and we do not want to miss any information.

## INTRODUCTION

The World Health Organization (WHO) defines palliative care as an approach that improves the quality of life (QOL) of patients and their families facing problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual [1]. It can be provided at any age and is not limited to the end of life, being appropriate at any stage (stable, unstable, deteriorating or terminal) in a serious illness (cancer and/or other disease). The palliative care should be applicable early in the course of illness and can be provided along with curative treatment or other therapies that are intended to prolong life, such as chemotherapy or radiation therapy. Worldwide, an estimated 40 million people are in need of palliative care each year, but only 14% receive it. The majority of adults in need of palliative care have serious diseases such as cardiovascular diseases (38.5%), cancer (34%) and chronic respiratory diseases (10.3%) [2].

Diabetes mellitus (DM) affects more than 400 million people, corresponding to 8.5% of adults worldwide [2]. The incidence of DM in patients receiving palliative care is higher than in general population due to several factors: age, diabetogenic drugs such as corticosteroids, metabolic changes due to chronic disease, etc. This association is intended to grow as a result of the rising burden on DM worldwide, ageing populations and the improved overall survival time in the last decades in several diseases [3]. The diagnosis of DM has already been made in the majority of patients who are referred to palliative care services. However, in patients receiving palliative care, DM can be secondary to drugs such as corticosteroids. Furthermore, DM is, by itself, an increased cause of palliative enrollment in some countries with advanced health system integration [4,5]. Evidence-based practice guidelines for the management of DM were developed by several scientific associations [6–9]. Nutrition, pharmacologic therapy, self-monitoring blood glucose and HbA1c targets should be individualized for each patient. Goals should be individualized based on

1  
2  
3 duration of DM, age or life expectancy, comorbid conditions, known cardiovascular disease or  
4 advanced microvascular complications, hypoglycemia unawareness, and individual patient  
5 considerations. Although it is usually suggested less restrictive glycemic targets for DM  
6 management in the context of palliative care, recommendations are mainly based on expert  
7 opinions. Indeed, there is a lack of suitable evidence base and randomized clinical trials in  
8 palliative care are scarce. To our best knowledge, the most resourceful nutritional approach, oral  
9 and injectable (non-insulin) agents, types of insulin or insulin regimens, are still unknown.

10  
11 Palliative medicine provides relief from pain and other distressing symptoms at any stage of the  
12 disease. Important hyperglycemic-related symptoms, such as polyuria, polydipsia and  
13 polyphagia, and DM-related acute complications, namely hypoglycemia, hyperglycemic  
14 hyperosmolar state and diabetic ketoacidosis, are of main concern and should be avoided. They  
15 can contribute to worsening patients' general condition and QOL, particularly acute complications,  
16 which commonly lead to hospital admission and additional consequences. Comfort, patient  
17 preferences, evaluation of oral intake, and preservation of QOL are of particular importance.

### 32 **Objectives**

33  
34 This systematic review was developed after a multidisciplinary discussion between the authors of  
35 shared doubts and concerns regarding DM management in palliative care. The aim of our  
36 systematic review is to assess the best management of DM in order to reduce important DM-  
37 related symptoms (polyuria, polydipsia, and polyphagia) and acute complications (hypoglycemia,  
38 hyperglycemic hyperosmolar state, and diabetic ketoacidosis) in patients receiving palliative care.  
39 The results of this systematic review could be important to improved patients' care and be a  
40 stimulus for additional studies regarding DM management in palliative care.

### 51 **METHODS AND ANALYSIS**

52  
53 The present protocol followed the preferred reporting items for systematic review and meta-  
54 analysis protocols (PRISMA-P) that was defined in 2015 [10], subsequent to the PRISMA  
55



1  
2  
3 Statement. The protocol is registered online on the International prospective register of systematic  
4 reviews, PROSPERO.

### 7 **Eligibility criteria**

8  
9 The population, intervention, comparator and outcomes as described by the PRISMA Statement  
10 [11] are reported below.

#### 13 Type of population

14  
15 We will include studies of diabetic adult ( $\geq 18$  years old) patients on palliative care. We will exclude  
16 studies with pediatric population, absence of DM, and with patients who are not in palliative care.

#### 19 Type of intervention

20  
21 We will include studies reporting the intervention: management of DM. Details regarding diet, oral  
22 and injectable (non-insulin) antidiabetic drugs, insulin regimens and blood glucose monitoring  
23 strategies will be evaluated. Different approaches according to etiology of DM, duration of DM,  
24 stage of palliative disease (stable, unstable, deteriorating, terminal) will also be assessed.

#### 29 Type of comparator

30  
31 The comparator item will be the different treatments and/or approaches used to manage DM in  
32 patients receiving palliative care.

#### 36 Type of outcome

37  
38 Primary outcomes will be the presence of symptoms (polyuria, polydipsia, and polyphagia) and  
39 acute complications (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic  
40 ketoacidosis) of DM. If data exists, we will also report the secondary outcomes: hospital admission  
41 due to DM-related complications, deaths due to DM-related complications, health-related QOL  
42 (objective measures), and glycemic control measured by HbA1c or average glycemia.

#### 48 Type of studies

49  
50 We will include studies of any design regarding DM treatment and management in adult patients  
51 on palliative care. We will include only studies with the minimum of 10 participants. We will exclude  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 editorials, comments, case reports, and other reviews and studies before 1990 (year of the first  
4 formal definition of palliative care by World Health Organization).  
5  
6

### 7 **Information sources**

8  
9 We will search the following electronic bibliographic databases: Ovid MEDLINE, Embase,  
10 PubMed Central, Web of Sciences, Cochrane Central Register of Controlled Trials (CENTRAL),  
11  
12 Cochrane Database of Systematic Reviews (CDSR), Scopus, Cumulative Index to Nursing and  
13 Allied Health Literature (CINAHL).  
14  
15

### 16 **Search strategy**

17  
18 The search will be conducted in December 2018. Core health bibliographic databases will be  
19 searched from January 1990 to December 2018.  
20  
21

22  
23 The search strategy will include only terms relating to or describing the intervention. The search  
24 strategy will be defined for Ovid MEDLINE and then will be adapted for use with other bibliographic  
25 databases. No filters or limitations were applied to the search strategy to ensure retrieval of pre-  
26 indexed materials. Only studies in English, Spanish and Portuguese will be included. The authors  
27 will also search for grey literature, including unpublished conference proceedings or abstracts  
28 from relevant specialty conferences. Reference lists of previous reviews and of included studies  
29 will also be screened looking for potential eligible studies. The full search strategy for each  
30 database is available in the supplementary material.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Study records**

#### 42 **Data management**

43  
44 We will apply the inclusion and exclusion criteria outlined above to the potential eligible studies  
45 retrieved using our search strategy. For studies selection we will use Covidence – Better  
46 Systematic Review Management [12]. All the records identified in the search strategy will be  
47 downloaded as Research Information Systems (RIS) files, and uploaded to EndNote (as a  
48 security copy) and to Covidence.  
49  
50  
51  
52  
53  
54

#### 55 **Selection process**

1  
2  
3 Covidence will automatically identify and exclude the duplicates. After obtaining the final  
4 potentially eligible articles to include in this systematic review, titles and abstracts will be screened  
5 by two independent reviewers. The conflicts will be solved by a third author not involved in voting  
6 the specific study. Potentially eligible studies will be uploaded into Covidence for full-text  
7 screening. Similarly, this process will be done by two independent reviewers. The same procedure  
8 will be applied and any disagreement between them will be resolved by a third reviewer.  
9

#### 15 Data collection process

16 Relevant data will be extracted into a predefined data extraction sheet. This data extraction sheet  
17 will be designed for the purpose of this study and will be piloted per the authors responsible for  
18 the data extraction with a minimum of 5 studies.  
19

20 Seven authors will extract data from the potential eligible studies. Each study will be double-  
21 reviewed: one author will extract the data and a second author will independently check the data  
22 extraction forms for accuracy and detail. Discrepancies between the authors will be solved by  
23 another author and discussed until reaching consensus. Data extraction will also be done using  
24 the software Covidence. Authors of eligible studies will be contacted by email to provide missing  
25 or additional data.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

#### 36 Data items

37 The data extraction sheet will contain information regarding study setting, study population,  
38 participant's characteristics, study methodology, life-threatening illness related data (etiology of  
39 disease, stage of palliative care), details of DM (type and duration of DM, usual treatment namely  
40 class of oral or injectable [non-insulin] antidiabetic drugs, type of insulin, insulin regimen), type of  
41 DM management used in the palliative care (diet, oral antidiabetic drugs, type of insulin, insulin  
42 regimen, blood glucose monitoring strategies) and information for assessment of the risk of bias.  
43 The frequency of DM-related symptoms (polyuria, polydipsia, and polyphagia) and DM-related  
44 acute complications (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic  
45 ketoacidosis) will be extracted and evaluated according to different DM approaches. Hospital  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 admission and deaths due to DM-related complications, QOL, HbA1c and average glycemia will  
4 also be extracted when available.  
5

#### 6 Outcomes and prioritization

7  
8 All the variables will be extracted as string variables. As mentioned on the type of outcomes, we  
9 will extract all the data available regardless if it is a main or additional outcome. We will not apply  
10 prioritization schemes as meta-analysis will not be performed.  
11  
12  
13

#### 14 Risk of bias in individual studies

15  
16 Two independent reviewers will assess the risk of bias and quality evidence of the eligible studies.  
17  
18 Disagreements between the review authors over the risk of bias will be resolved by a third author  
19 and discussed until reaching consensus. We will use the Study Quality Assessment Tools of the  
20 *National Institutes of Health* [13]. Any discrepancies or unusual patterns will be checked with the  
21 study investigator.  
22  
23  
24  
25  
26  
27

#### 28 Data synthesis

29  
30 The results will be summarized in tables containing the population, type of treatment and/or  
31 approach for DM, and the outcomes. The comparison between these variables will be further  
32 described. We will write a descriptive synthesis of the findings from the included studies,  
33 structured from the patient's characteristics, type of diabetes management, data from the disease  
34 referred to palliative care, and acute complications and symptoms of DM. If data exists, we will  
35 provide summaries of intervention effects for each study.  
36  
37  
38  
39  
40  
41  
42

#### 43 Analysis of subgroups or subsets

44  
45 If there is enough data, we will perform sub-group analysis by age groups, sex, etiology of the  
46 disease requiring palliative care, stage of palliative care, type of DM, different settings (acute or  
47 primary care sector, professional or family care), and study design.  
48  
49  
50

#### 51 Patient and public involvement

52 Patients and public were not involved in this study.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Ethics and dissemination:** The systematic review methodology does not require ethical  
4 approval due to the nature of the study design. The results of the systematic review will be  
5 published in a peer-reviewed journal and publically available. It will also be disseminated  
6 electronically and in print.  
7  
8  
9

10  
11 **Authors' contributions:** RBS is the primary author for the study and approved the final  
12 manuscript. RBS and MSP conceived, designed the study and drafted the protocol. MSP is the  
13 corresponding author. MSP and LÖ performed the full search strategy for each database. LÖ  
14 provided feedback on study protocol design and critically revised earlier versions of the  
15 manuscript. BA, VSA, RB, VG, MJMR and DC critically revised earlier drafts of the manuscript for  
16 intellectual content. All the authors read and approved the final manuscript.  
17  
18  
19

20 **Funding statement:** This study did not require any funding.  
21

22 **Competing interests:** None.  
23

24 **Data sharing:** No additional data available.  
25

26 **Patient consent:** Not required per the study design.  
27  
28  
29

## 30 REFERENCES 31 32 33 34

- 35 1 World Health Organization. WHO | WHO Definition of Palliative Care. WHO.  
36 2012.<http://www.who.int/cancer/palliative/definition/en/> (accessed 14 Nov 2018).  
37
- 38 2 World Health Organization. WHO Fact Sheets on Palliative Care. [http://www.who.int/news-](http://www.who.int/news-room/fact-sheets/detail/palliative-care)  
39 room/fact-sheets/detail/palliative-care (accessed 14 Nov 2018).  
40
- 41 3 Surveillance Research Program NCI. SEER\*Explorer: An interactive website for SEER  
42 cancer statistics. <https://seer.cancer.gov/explorer/> (accessed 14 Nov 2018).  
43
- 44 4 Johnston GM, Lethbridge L, Talbot P, *et al*. Identifying persons with diabetes who could  
45 benefit from a palliative approach to care. *Can J diabetes* 2015;**39**:29–35.  
46 doi:10.1016/j.jcjd.2014.01.009  
47
- 48 5 The World Hospice Palliative Care Association. WHO Global Atlas on Palliative Care At  
49 the End of Life. <http://www.thewhpc.org/resources/global-atlas-on-end-of-life-care>  
50  
51  
52  
53  
54  
55  
56  
57

- (accessed 14 Nov 2018).
- 6 American Diabetes Association AD. 11. Older Adults: Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018;**41**:S119–25. doi:10.2337/dc18-S011
  - 7 Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type 2 diabetes in older people. *Diabetes Res Clin Pract* 2014;**103**:538–40. doi:10.1016/j.diabres.2014.03.005
  - 8 Davies MJ, D'Alessio DA, Fradkin J, *et al.* Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018;**41**:2669–701. doi:10.2337/dci18-0033
  - 9 Garber AJ, Abrahamson MJ, Barzilay JI, *et al.* Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 Executive Summary. *Endocr Pract* 2018;**24**:91–120. doi:10.4158/CS-2017-0153
  - 10 Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;**350**:g7647. doi:10.1136/BMJ.G7647
  - 11 Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS Med* 2009;**6**:e1000100. doi:10.1371/journal.pmed.1000100
  - 12 Babineau J. Product Review: Covidence (Systematic Review Software). *J Can Heal Libr Assoc / J l'Association des bibliothèques la santé du Canada* 2014;**35**:68. doi:10.5596/c14-016
  - 13 National Heart Lung and Blood Institute. Study Quality Assessment Tools - NHLBI, NIH. 2016. <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> (accessed 21 Nov 2018).

1  
2  
3 **Diabetes-related symptoms, acute complications and**  
4 **management of diabetes mellitus in palliative care: a**  
5 **systematic review.**  
6  
7  
8  
9

10  
11 Search strategy for **PubMed**:  
12  
13

14 (((((((((diabetes mellitus[MeSH Terms]) OR diabet\*[Title/Abstract])) OR  
15 T1DM[Title/Abstract]) OR T2DM[Title/Abstract]) OR NIDDM[Title/Abstract]) OR  
16 IDDM[Title/Abstract]) OR hyperglycemia[MeSH Major Topic]) OR  
17 hyperglycemia\*[Title/Abstract]) AND (((((((((palliative care[MeSH Major Topic]) OR  
18 terminal care[MeSH Major Topic]) OR palliative[Title/Abstract]) OR "terminal  
19 care"[Title/Abstract]) OR "supportive care"[Title/Abstract]) OR "Terminal patient"  
20 [Title/Abstract]) OR "terminal patients" [Title/Abstract]) OR "End of Life  
21 Care"[Title/Abstract]) OR "Terminal Phase"[Title/Abstract])  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
<b>ADMINISTRATIVE INFORMATION</b>					
<b>Title</b>					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Registration</b>	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	3
<b>Authors</b>					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	2, 3
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11
<b>Amendments</b>	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Support</b>					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
<b>INTRODUCTION</b>					
<b>Rationale</b>	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5, 6
<b>Objectives</b>	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	6
<b>METHODS</b>					



Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
<b>DATA</b>					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA

# BMJ Open

## Diabetes-related symptoms, acute complications and management of diabetes mellitus of patients who are receiving palliative care: a protocol for a systematic review.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028604.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Mar-2019
Complete List of Authors:	<p>Bettencourt-Silva, Rita; Centro Hospitalar Universitário São João, Department of Endocrinology, Diabetes and Metabolism; Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, University of Porto</p> <p>Aguiar, Beatriz; Unidade de Saúde de Ilha de São Miguel, Unidade de Saúde de Rabo de Peixe</p> <p>Sá-Araújo, Vânia; Instituto Português de Oncologia do Porto Francisco Gentil, Department of Palliative Care</p> <p>Barreira, Rosa; Unidade de Saúde Familiar Maresia, Unidade Local de Saúde de Matosinhos</p> <p>Guedes, Vânia; Unidade de Saúde Familiar São João do Porto, Agrupamento de Centros de Saúde (ACES) do Porto Ocidental</p> <p>Marques Ribeiro, Maria João; Centro Hospitalar Universitário São João, Department of Medical Oncology</p> <p>Carvalho, Davide ; Centro Hospitalar Universitário de São João, Department of Endocrinology, Diabetes and Metabolism; Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, University of Porto</p> <p>Östlundh, Linda; United Arab Emirates University College of Medicine and Health Sciences, National Medical Library</p> <p>Paulo, Marília Silva; United Arab Emirates University College of Medicine and Health Sciences, Institute of Public Health; Universidade Nova de Lisboa Instituto de Higiene e Medicina Tropical,</p>
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Palliative care
Keywords:	DIABETES & ENDOCRINOLOGY, PALLIATIVE CARE, Adult palliative care < PALLIATIVE CARE, General diabetes < DIABETES & ENDOCRINOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Diabetes-related symptoms, acute complications and management of diabetes**  
4 **mellitus of patients who are receiving palliative care: a protocol for a systematic**  
5 **review.**  
6  
7  
8  
9

10  
11 Rita Bettencourt-Silva<sup>1,2,3</sup>, Beatriz Aguiar<sup>4</sup>, Vânia Sá-Araújo<sup>5</sup>, Rosa Barreira<sup>6</sup>, Vânia Guedes<sup>7</sup>,  
12 Maria João Marques Ribeiro<sup>8</sup>, Davide Carvalho<sup>1,2,3</sup>, Linda Östlundh<sup>9</sup>, Marília Silva Paulo<sup>10,11\*</sup>  
13  
14  
15

16  
17  
18 <sup>1</sup> Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São  
19 João, Porto, Portugal.  
20

21  
22 <sup>2</sup> Faculty of Medicine of University of Porto, Porto, Portugal.  
23

24 <sup>3</sup> Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.  
25

26 <sup>4</sup> Unidade de Saúde da Ilha de São Miguel, Unidade de Saúde de Rabo de Peixe, Ribeira Grande,  
27 São Miguel, Açores, Portugal.  
28

29  
30 <sup>5</sup> Department of Palliative Care, Instituto Português de Oncologia do Porto Francisco Gentil,  
31 Porto, Portugal.  
32

33  
34 <sup>6</sup> Unidade de Saúde Familiar Maresia, Unidade Local de Saúde de Matosinhos, Matosinhos,  
35 Portugal.  
36

37  
38 <sup>7</sup> Unidade de Saúde Familiar São João do Porto, Agrupamento de Centros de Saúde (ACES) do  
39 Porto Ocidental, Porto, Portugal.  
40

41  
42 <sup>8</sup> Department of Medical Oncology, Centro Hospitalar Universitário de São João, Porto, Portugal.  
43

44  
45 <sup>9</sup> National Medical Library, College of Medicine and Health Sciences, United Arab Emirates  
46 University. Al Ain, United Arab Emirates.  
47

48  
49 <sup>10</sup> Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates  
50 University. Al Ain, United Arab Emirates.  
51

52  
53 <sup>11</sup> Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade  
54 Nova de Lisboa, Lisboa, Portugal.  
55  
56  
57

1  
2  
3 \* Address of corresponding author:  
4

5 Marília Silva Paulo

6  
7 mariliap@uaeu.ac.ae

8  
9 Institute of Public Health

10  
11 College of Medicine and Health Sciences

12  
13 United Arab Emirates University.

14  
15 PO Box: 17666, Al Ain, United Arab Emirates.  
16  
17

18  
19  
20 Word count: 1718  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Worldwide, an estimated 40 million people are in need of palliative care each year, but only 14% receive it. The incidence of diabetes mellitus (DM) in patients receiving palliative care is higher than in the general population. This association is intended to grow as result of the rising burden on DM worldwide, ageing populations and the improved overall survival time of several diseases over the last few decades. Recommendations for DM management in the context of palliative care are mainly based on expert opinion. There is a lack of suitable evidence base and randomized clinical trials in palliative care are scarce. The aim of our systematic review is to assess the best DM management practices in order to reduce important DM-related symptoms and acute complications in patients receiving palliative care.

**Methods and analysis:** The authors will study the DM treatment and management literature, surveying the different approaches employed in palliative care adult patients. Data sources will include Ovid MEDLINE, Embase, PubMed, Web of Sciences, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, CINAHL, and grey literature. Details regarding diet, oral and injectable glucose-lowering medicines, insulin regimens and blood glucose monitoring strategies will be evaluated. Primary outcomes will be the presence of symptoms (polyuria, polydipsia, and polyphagia) and acute complications of DM (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic ketoacidosis). Secondary outcomes will be hospital admissions and deaths due to DM-related complications, health-related quality of life, and glycemic control.

**Ethics and dissemination:** The systematic review methodology does not require ethics approval due to the nature of the study design. The results of the systematic review will be published in a peer-reviewed journal and will be publically available.

**PROSPERO registration number:** CRD42018115772

**Strengths and limitations of this study:**

- The present protocol is an outline of the systematic review specificities that will guide the authors while conducting the systematic review on the diabetes-related symptoms, acute complications and management of diabetes mellitus in palliative care.
- The search strategy will be limited to studies other than in English, Portuguese or Spanish language and before 1990.
- One of diabetes mellitus related outcomes will be the HbA1c, this is an average measure of blood glucose and many factors can affect its accuracy, but we will consider this during risk of bias and quality of evidence assessment.
- The inclusion of grey literature will make this study wider in terms of included information.
- This systematic review will include studies of any design because, as far as we know, this is the first systematic review on the diabetes-related symptoms and complications in palliative care.

## INTRODUCTION

The World Health Organization (WHO) defines palliative care as an approach that improves the quality of life (QOL) of patients and their families facing problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual [1]. Palliative care can be provided to a person of any age and it is not limited to patients at the end of life, is appropriate at any stage (stable, unstable, deteriorating or terminal) of serious illnesses (cancer and/or another disease) [2]. Palliative care should be applicable early in the course of illness and it can be provided alongside curative treatment or other therapies that are intended to prolong life, such as chemotherapy or radiation therapy. Worldwide, an estimated 40 million people are in need of palliative care each year, but only 14% receive it [3]. The majority of adults in need of palliative care have serious diseases such as cardiovascular diseases (38.5%), cancer (34%) and chronic respiratory diseases (10.3%) [3].

Diabetes mellitus (DM) affects more than 400 million people, corresponding to 8.5% of adults worldwide [3]. The incidence of DM in patients receiving palliative care is higher than in the general population due to several factors, such as age, use of diabetogenic drugs such as corticosteroids and metabolic changes due to chronic disease. This association is intended to grow as a result of the rising burden of DM worldwide, ageing populations and the improved overall survival time of several diseases over the last few decades [4,5]. The diagnosis of DM has already been made in the majority of patients who are referred to palliative care services [6]. However, in patients receiving palliative care, DM can be secondary to drugs such as corticosteroids [7]. Furthermore, DM is, by itself, an increased cause of palliative enrollment in some countries with advanced health system integration [8,9]. Evidence-based practice guidelines for the management of DM have been developed by several scientific associations [10–13] which highlight that nutrition, pharmacologic therapy, self-monitoring blood glucose and



1  
2  
3 HbA1c targets should be individualized for each patient. Additionally, goals should be  
4 individualized based on the duration of DM, age or life expectancy, comorbid conditions, known  
5 cardiovascular disease or advanced microvascular complications, hypoglycemia unawareness,  
6 and individual patient considerations. Although less restrictive glycemic targets for DM  
7 management in the context of palliative care are usually suggested, recommendations are mainly  
8 based on expert opinion [10]. Indeed, there is a lack of relevant evidence particularly from  
9 randomized clinical trials that guides DM management in the context of palliative care. To the best  
10 of our knowledge, the most resourceful nutritional approach, oral and injectable (non-insulin)  
11 agents, types of insulin or insulin regimens, are still unknown to manage DM in the palliative  
12 context.

13  
14 Palliative medicine manages the whole person, providing not only relief from pain and other distressing  
15 symptoms at any stage of the disease, but also treating concomitant chronic diseases. Comfort, patient  
16 preferences and preservation of QOL are of particular importance. As such, treatment of hyperglycemia-  
17 related symptoms and DM-related acute complications, that can contribute to worsening patients'  
18 general condition and QOL and lead to hospital admission, is paramount. Therefore,  
19 interdisciplinary team care and early referral to relevant clinicians are essential.

### 20 21 22 **Objectives**

23  
24 This systematic review was developed after a multidisciplinary discussion between the authors of  
25 shared doubts and concerns regarding DM management in the context of palliative care. The aim  
26 of our systematic review is to assess the best management of DM in order to reduce important  
27 DM-related symptoms (polyuria, polydipsia, and polyphagia) and acute complications  
28 (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic ketoacidosis) in patients  
29 receiving palliative care. The results of this systematic review may guide practices to improve  
30 patient care and be a stimulus for additional studies regarding DM management in palliative care.

### 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 **METHODS AND ANALYSIS**

1  
2  
3 The present protocol followed the preferred reporting items for systematic reviews and meta-  
4 analysis protocols (PRISMA-P) that was defined in 2015 [14], subsequent to the PRISMA  
5 Statement. The protocol is registered online on the International prospective register of systematic  
6 reviews, PROSPERO: CRD42018115772.  
7  
8  
9

### 11 **Eligibility criteria**

12  
13 The population, intervention, comparator and outcomes as described by the PRISMA Statement  
14 [15] are reported below.  
15

#### 16 **Type of population**

17  
18 We will include studies of diabetic adult ( $\geq 18$  years old) patients receiving palliative care. We will  
19  
20 exclude studies with the pediatric population, those who do not have DM, and the patients who  
21  
22 are not in palliative care.  
23  
24

#### 25 **Type of intervention**

26  
27 We will include primary studies reporting the intervention: management of DM. Details regarding  
28  
29 diet, oral and injectable (non-insulin) glucose-lowering drugs, insulin regimens and blood glucose  
30  
31 monitoring strategies will be evaluated. Different approaches according to the etiology of DM,  
32  
33 duration of DM, stage of palliative disease (stable, unstable, deteriorating, terminal) will also be  
34  
35 assessed.  
36  
37

#### 38 **Type of comparator**

39  
40 The comparator item will be the different treatments and/or approaches used to manage DM in  
41  
42 patients receiving palliative care.  
43  
44

#### 45 **Type of outcome**

46  
47 Primary outcomes will be the presence of symptoms (polyuria, polydipsia, and polyphagia) and  
48  
49 acute complications of DM (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic  
50  
51 ketoacidosis). If data exists, we will also report the secondary outcomes: hospital admissions due  
52  
53 to DM-related complications, deaths due to DM-related complications, health-related QOL  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (objective measures), advanced care planning, documented advance care plans and glycemc  
4 control measured by HbA1c or average glycemia.  
5

#### 6 7 Type of studies

8  
9 We will include studies of any design regarding DM treatment and management in adult patients  
10 receiving palliative care. We will include only studies with a minimum of 10 participants. We will  
11 exclude editorials, comments, case reports, and other reviews and studies before 1990 (year of  
12 the first formal definition of palliative care by the World Health Organization).  
13  
14  
15

#### 16 17 **Information sources**

18  
19 We will search the following electronic bibliographic databases: Ovid MEDLINE, Embase,  
20 PubMed Central, Web of Sciences, Cochrane Central Register of Controlled Trials (CENTRAL),  
21 Cochrane Database of Systematic Reviews (CDSR), Scopus, Cumulative Index to Nursing and  
22 Allied Health Literature (CINAHL). Grey literature will be searched at the Grey Literature Report  
23 and Open Grey databases. The inclusion and exclusion criteria applied will be the same used for  
24 medical bibliographic databases.  
25  
26  
27  
28  
29  
30  
31

#### 32 33 **Search strategy**

34  
35 The search will be conducted as soon as this protocol is published. Core health bibliographic  
36 databases will be searched from January 1990 to the current time.  
37

38  
39 The search strategy will include only terms relating to or describing the intervention. The search  
40 strategy will be defined for Ovid MEDLINE and then will be adapted for use with other bibliographic  
41 databases. No filters or limitations will be applied to the search strategy to ensure retrieval of pre-  
42 indexed materials. Only studies in English, Spanish and Portuguese will be included. Grey  
43 literature will include unpublished conference proceedings or abstracts from relevant speciality  
44 conferences. Reference lists of previous reviews and of included studies will also be screened  
45 looking for potentially eligible studies. The full search strategy for each database is available in  
46 the supplementary material.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Study records

### Data management

We will apply the inclusion and exclusion criteria outlined above to the potentially eligible studies retrieved using our search strategy. For studies selection, we will use Covidence – Better Systematic Review Management [16]. All the records identified in the search strategy will be downloaded as Research Information Systems (RIS) files and uploaded to EndNote (as a security copy) and to Covidence.

### Selection process

Covidence will automatically identify and exclude the duplicates. After obtaining the final potentially eligible articles to include in this systematic review, titles and abstracts will be screened by two independent reviewers. The two independent reviewers will screen all titles and abstracts considering the inclusion and exclusion criteria outlined. Based on that they will vote the potentially eligible study to be included or excluded. Each study will be voted by the two authors and conflicts will be solved by a third author not involved in screening the papers. Potentially eligible studies will be uploaded into Covidence for full-text screening. Similarly, this process will be done by two independent reviewers. The same procedure will be applied and any disagreement between them will be resolved by a third reviewer.

### Data collection process

Relevant data will be extracted into a predefined data extraction sheet. This data extraction sheet will be designed for the purpose of this study and will be piloted per the authors responsible for the data extraction with a minimum of 5 studies.

Seven authors will extract data from potentially eligible studies. Each study will be double-reviewed: one author will extract the data and a second author will independently check the data extraction forms for accuracy and detail. Discrepancies between the authors will be solved by another author and discussed until reaching consensus. Data extraction will also be done using

1  
2  
3 the software Covidence. Authors of eligible studies will be contacted by email to provide missing  
4 or additional data.  
5

#### 6 7 Data items

8  
9 The data extraction sheet will contain information regarding study setting, study population,  
10 participant's characteristics, study methodology, life-threatening illness related data (etiology of  
11 disease, stage of palliative care), details of DM (type and duration of DM, usual treatment namely  
12 class of oral or injectable (non-insulin) glucose-lowering drugs, type of insulin, insulin regimen),  
13 type of DM management used in the palliative care (diet, oral glucose-lowering medicines, type  
14 of insulin, insulin regimen, blood glucose monitoring strategies) and information for assessment  
15 of the risk of bias. The frequency of DM-related symptoms (polyuria, polydipsia, and polyphagia)  
16 and DM-related acute complications (hypoglycemia, hyperglycemic hyperosmolar state, and  
17 diabetic ketoacidosis) will be extracted and evaluated according to different DM approaches.  
18 Hospital admission and deaths due to DM-related complications, QOL, advanced care planning,  
19 documented advance care plans, HbA1c and average glycemia will also be extracted when  
20 available.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

#### 34 35 Outcomes and prioritization

36  
37 All the variables will be extracted as string variables. As mentioned on the type of outcomes, we  
38 will extract all the data available regardless if it is a main or additional outcome. We will not apply  
39 prioritization schemes as meta-analysis will not be performed.  
40  
41  
42

#### 43 44 Risk of bias in individual studies

45  
46 Two independent reviewers will assess the risk of bias and quality evidence of the eligible studies  
47 using the Study Quality Assessment Tools of the *National Institutes of Health* [17]. Disagreements  
48 between the review authors over the risk of bias will be resolved by a third author and discussed  
49 until reaching consensus. Any discrepancies or unusual patterns will be checked with the study  
50 investigator, although we will not exclude studies based on their quality report, we will just  
51 describe it  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Data synthesis

The results will be summarized in tables containing the year, country, population, type of treatment and/or approach for DM, and the outcomes. The comparison between these variables will be further described. We will write a descriptive synthesis of the findings from the included studies, structured from the patient's characteristics, type of diabetes management, data from the disease referred to palliative care, and acute complications and symptoms of DM. If data exists, we will provide summaries of intervention effects for each study.

### Analysis of subgroups or subsets

If there is enough data, we will perform sub-group analysis by age groups, sex, etiology of the disease requiring palliative care, stage of palliative care, type of DM, different settings (acute or primary care sector, professional or family care), and study design.

### Patient and public involvement

Patients and the public were not involved in this study.

**Ethics and dissemination:** The systematic review methodology does not require ethics approval due to the nature of the study design. The results of the systematic review will be published in a peer-reviewed journal and will be publically available. It will also be disseminated electronically and in printed versions.

**Authors' contributions:** RBS is the primary author for the study and approved the final manuscript. RBS and MSP conceived, designed the study and drafted the protocol. MSP is the corresponding author. MSP and LÖ performed the full search strategy for each database. LÖ provided feedback on study protocol design and critically revised earlier versions of the manuscript. BA, VSA, RB, VG, MJMR and DC critically revised earlier drafts of the manuscript for intellectual content. All the authors read and approved the final manuscript.

**Funding statement:** This study did not require any funding.

**Competing interests:** None.

**Data sharing:** No additional data available.

**Patient consent:** Not required per the study design.

## REFERENCES

- 1 World Health Organization. WHO | WHO Definition of Palliative Care. WHO. 2012.<http://www.who.int/cancer/palliative/definition/en/> (accessed 14 Nov 2018).
- 2 World Health Organization. Palliative Care: symptom management and end-of-life care INTEGRATED MANAGEMENT OF ADOLESCENT AND ADULT ILLNESS INTERIM GUIDELINES FOR FIRST-LEVEL FACILITY HEALTH WORKERS. 2004. <https://www.who.int/3by5/publications/documents/en/genericpalliativecare082004.pdf> (accessed 10 Mar 2019).
- 3 World Health Organization. WHO Fact Sheets on Palliative Care. <http://www.who.int/news-room/fact-sheets/detail/palliative-care> (accessed 14 Nov 2018).
- 4 Surveillance Research Program NCI. SEER\*Explorer: An interactive website for SEER cancer statistics. <https://seer.cancer.gov/explorer/> (accessed 14 Nov 2018).
- 5 Quinn K, Hudson P, Dunning T. Diabetes Management in Patients Receiving Palliative Care. *J Pain Symptom Manage* 2006;**32**:275–86. doi:10.1016/j.jpainsymman.2006.03.011
- 6 Ahmad F, Doctor SG, Mills C, *et al*. Diabetes in palliative care. 2005;**3**:3–6.
- 7 Li X, Beel A, Hiebert T, *et al*. Corticosteroid-Induced Diabetes in Palliative Care. *J Palliat Med* 2012;**15**:681–9. doi:10.1089/jpm.2011.0513
- 8 Johnston GM, Lethbridge L, Talbot P, *et al*. Identifying persons with diabetes who could benefit from a palliative approach to care. *Can J diabetes* 2015;**39**:29–35. doi:10.1016/j.jcjd.2014.01.009
- 9 The World Hospice Palliative Care Association. WHO Global Atlas on Palliative Care At the End of Life. <http://www.thewhpc.org/resources/global-atlas-on-end-of-life-care> (accessed 14 Nov 2018).

- 1  
2  
3 10 American Diabetes Association. 11. Older Adults: Standards of Medical Care in Diabetes-  
4 2018. *Diabetes Care* 2018;**41**:S119–25. doi:10.2337/dc18-S011  
5  
6  
7 11 Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type 2 diabetes in  
8 older people. *Diabetes Res Clin Pract* 2014;**103**:538–40.  
9 doi:10.1016/j.diabres.2014.03.005  
10  
11  
12 12 Davies MJ, D'Alessio DA, Fradkin J, *et al.* Management of Hyperglycemia in Type 2  
13 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and  
14 the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018;**41**:2669–  
15 701. doi:10.2337/dci18-0033  
16  
17  
18  
19 13 Garber AJ, Abrahamson MJ, Barzilay JI, *et al.* Consensus statement by the American  
20 Association of Clinical Endocrinologists and American College of Endocrinology on the  
21 comprehensive type 2 diabetes management algorithm – 2018 Executive Summary.  
22 *Endocr Pract* 2018;**24**:91–120. doi:10.4158/CS-2017-0153  
23  
24  
25  
26 14 Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic review and  
27 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*  
28 2015;**350**:g7647. doi:10.1136/BMJ.G7647  
29  
30  
31  
32 15 Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA Statement for Reporting Systematic  
33 Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions:  
34 Explanation and Elaboration. *PLoS Med* 2009;**6**:e1000100.  
35 doi:10.1371/journal.pmed.1000100  
36  
37  
38  
39 16 Babineau J. Product Review: Covidence (Systematic Review Software). *J Can Heal Libr*  
40 *Assoc / J l'Association des bibliothèques la santé du Canada* 2014;**35**:68. doi:10.5596/c14-  
41 016  
42  
43  
44 17 National Heart Lung and Blood Institute. Study Quality Assessment Tools - NHLBI, NIH.  
45 2016. <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> (accessed 21  
46 Nov 2018).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Diabetes-related symptoms, acute complications and**  
4 **management of diabetes mellitus in palliative care: a**  
5 **systematic review.**  
6  
7  
8  
9

10  
11 Search strategy for **PubMed**:

12  
13  
14 ((((((((((diabetes mellitus[MeSH Terms]) OR diabet\*[Title/Abstract])) OR  
15 T1DM[Title/Abstract]) OR T2DM[Title/Abstract]) OR NIDDM[Title/Abstract]) OR  
16 IDDM[Title/Abstract]) OR "glucose lowering medicine\*[Title/Abstract]) OR  
17 hyperglycemia[MeSH Major Topic]) OR hyperglycemia\*[Title/Abstract]) AND  
18 ((((((((((palliative care[MeSH Major Topic]) OR terminal care[MeSH Major Topic]) OR  
19 palliative[Title/Abstract]) OR "terminal care"[Title/Abstract]) OR "supportive  
20 care"[Title/Abstract]) OR "Terminal patient" [Title/Abstract]) OR "terminal patients"  
21 [Title/Abstract]) OR "End of Life Care"[Title/Abstract]) OR "Terminal  
22 Phase"[Title/Abstract])  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
<b>ADMINISTRATIVE INFORMATION</b>					
<b>Title</b>					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Registration</b>	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	3
<b>Authors</b>					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	2, 3
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11
<b>Amendments</b>	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Support</b>					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
<b>INTRODUCTION</b>					
<b>Rationale</b>	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5, 6
<b>Objectives</b>	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	6
<b>METHODS</b>					

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
<b>DATA</b>					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	NA

# BMJ Open

## Diabetes-related symptoms, acute complications and management of diabetes mellitus of patients who are receiving palliative care: a protocol for a systematic review.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028604.R2
Article Type:	Protocol
Date Submitted by the Author:	01-May-2019
Complete List of Authors:	<p>Bettencourt-Silva, Rita; Centro Hospitalar Universitário São João, Department of Endocrinology, Diabetes and Metabolism; Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, University of Porto</p> <p>Aguiar, Beatriz; Unidade de Saúde de Ilha de São Miguel, Unidade de Saúde de Rabo de Peixe</p> <p>Sá-Araújo, Vânia; Instituto Português de Oncologia do Porto Francisco Gentil, Department of Palliative Care</p> <p>Barreira, Rosa; Unidade de Saúde Familiar Maresia, Unidade Local de Saúde de Matosinhos</p> <p>Guedes, Vânia; Unidade de Saúde Familiar São João do Porto, Agrupamento de Centros de Saúde (ACES) do Porto Ocidental</p> <p>Marques Ribeiro, Maria João; Centro Hospitalar Universitário São João, Department of Medical Oncology</p> <p>Carvalho, Davide ; Centro Hospitalar Universitário de São João, Department of Endocrinology, Diabetes and Metabolism; Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, University of Porto</p> <p>Östlundh, Linda; United Arab Emirates University College of Medicine and Health Sciences, National Medical Library</p> <p>Paulo, Marília Silva; United Arab Emirates University College of Medicine and Health Sciences, Institute of Public Health; Universidade Nova de Lisboa Instituto de Higiene e Medicina Tropical,</p>
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Palliative care
Keywords:	DIABETES & ENDOCRINOLOGY, PALLIATIVE CARE, Adult palliative care < PALLIATIVE CARE, General diabetes < DIABETES & ENDOCRINOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Diabetes-related symptoms, acute complications and management of diabetes**  
4 **mellitus of patients who are receiving palliative care: a protocol for a systematic**  
5 **review.**  
6  
7  
8  
9

10  
11 Rita Bettencourt-Silva<sup>1,2,3</sup>, Beatriz Aguiar<sup>4</sup>, Vânia Sá-Araújo<sup>5</sup>, Rosa Barreira<sup>6</sup>, Vânia Guedes<sup>7</sup>,  
12 Maria João Marques Ribeiro<sup>8</sup>, Davide Carvalho<sup>1,2,3</sup>, Linda Östlundh<sup>9</sup>, Marília Silva Paulo<sup>10,11\*</sup>  
13  
14  
15

16  
17  
18 <sup>1</sup> Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São  
19 João, Porto, Portugal.  
20

21  
22 <sup>2</sup> Faculty of Medicine of University of Porto, Porto, Portugal.  
23

24 <sup>3</sup> Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.  
25

26 <sup>4</sup> Unidade de Saúde da Ilha de São Miguel, Unidade de Saúde de Rabo de Peixe, Ribeira Grande,  
27 São Miguel, Açores, Portugal.  
28

29  
30 <sup>5</sup> Department of Palliative Care, Instituto Português de Oncologia do Porto Francisco Gentil,  
31 Porto, Portugal.  
32

33  
34 <sup>6</sup> Unidade de Saúde Familiar Maresia, Unidade Local de Saúde de Matosinhos, Matosinhos,  
35 Portugal.  
36

37  
38 <sup>7</sup> Unidade de Saúde Familiar São João do Porto, Agrupamento de Centros de Saúde (ACES) do  
39 Porto Ocidental, Porto, Portugal.  
40

41  
42 <sup>8</sup> Department of Medical Oncology, Centro Hospitalar Universitário de São João, Porto, Portugal.  
43

44  
45 <sup>9</sup> National Medical Library, College of Medicine and Health Sciences, United Arab Emirates  
46 University. Al Ain, United Arab Emirates.  
47

48  
49 <sup>10</sup> Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates  
50 University. Al Ain, United Arab Emirates.  
51

52  
53 <sup>11</sup> Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade  
54 Nova de Lisboa, Lisboa, Portugal.  
55  
56  
57

1  
2  
3 \* Address of corresponding author:  
4

5 Marília Silva Paulo

6  
7 mariliap@uaeu.ac.ae

8  
9 Institute of Public Health

10  
11 College of Medicine and Health Sciences

12  
13 United Arab Emirates University.

14  
15 PO Box: 17666, Al Ain, United Arab Emirates.  
16  
17

18  
19  
20 Word count: 1718  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Worldwide, an estimated 40 million people are in need of palliative care each year, but only 14% receive it. The incidence of diabetes mellitus (DM) in patients receiving palliative care is higher than in the general population. This association is intended to grow as result of the rising burden of DM worldwide, ageing populations and the improved overall survival time of several diseases over the last few decades. Recommendations for DM management in the context of palliative care are mainly based on expert opinion as there is a lack of suitable evidence base and randomized clinical trials in palliative care are scarce. The aim of our systematic review is to identify the best DM management practices in order to reduce important DM-related symptoms and acute complications in patients receiving palliative care.

**Methods and analysis:** The authors will study the DM treatment and management literature, surveying the different approaches employed to treat adult palliative patients. Core health bibliographic databases will be searched from January 1990 to May 2019. Data sources will include Ovid MEDLINE, Embase, PubMed, Web of Sciences, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, CINAHL, and grey literature. Details regarding diet, oral and injectable glucose-lowering medicines, insulin regimens and blood glucose monitoring strategies will be evaluated. We defined the primary outcomes to compare between DM management approaches as the presence of symptoms (polyuria, polydipsia, and polyphagia) and acute complications of DM (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic ketoacidosis), and secondary outcomes as hospital admissions and deaths due to DM-related complications, health-related quality of life, and glycemic control.

**Ethics and dissemination:** The systematic review methodology does not require ethics approval due to the nature of the study design. The results of the will be published in a peer-reviewed journal and will be publically available.

**PROSPERO registration number:** CRD42018115772



**Strengths and limitations of this study:**

- The present protocol is an outline of the systematic review specificities that will guide the authors while conducting the systematic review on the diabetes-related symptoms, acute complications and management of diabetes mellitus in palliative care.
- Limitations of this review include the exclusion of papers reported in languages other than English, Portuguese or Spanish and those published prior to 1990.
- The inclusion of grey literature will broaden this study in terms of included information.
- This systematic review will include primary studies of any design because, as far as we know, this is the first systematic review on the diabetes-related symptoms and complications in palliative care.

## INTRODUCTION

The World Health Organization (WHO) defines palliative care as an approach that improves the quality of life (QOL) of patients and their families facing problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual [1]. Palliative care can be provided to a person of any age and it is not limited to patients who are actively dying, is appropriate at any stage (stable, unstable, deteriorating or terminal) of serious illnesses (cancer and/or another disease) [2]. Palliative care is best introduced early in the course of illness and it can be provided alongside curative treatment or other therapies that are intended to prolong life, such as chemotherapy or radiation therapy. Worldwide, an estimated 40 million people are in need of palliative care each year, but only 14% receive it [3]. The majority of adults in need of palliative care have serious diseases such as cardiovascular diseases (38.5%), cancer (34%) and chronic respiratory diseases (10.3%) [3].

Diabetes mellitus (DM) affects more than 400 million people, corresponding to 8.5% of adults worldwide [3]. The incidence of DM in patients receiving palliative care is higher than in the general population due to several factors, such as age, use of diabetogenic drugs such as corticosteroids and metabolic changes due to chronic disease. This association is intended to grow as a result of the rising burden of DM worldwide, ageing populations and the improved overall survival time of several diseases over the last few decades [4]. The diagnosis of DM has already been made in the majority of patients who are referred to palliative care services. Furthermore, DM is, by itself, an increased cause of palliative enrollment in some countries with advanced health system integration as it can be considered as a life-threatening illness [5–7]. Evidence-based practice guidelines for the management of DM have been developed by several scientific associations [8–12] which highlight that nutrition, pharmacologic therapy, self-monitoring blood glucose and HbA1c targets should be individualized for each patient. Additionally, goals

1  
2  
3 should be individualized based on the duration of DM, age or life expectancy, comorbid  
4 conditions, known cardiovascular disease or advanced microvascular complications,  
5 hypoglycemia unawareness, and individual patient considerations [13]. Although less restrictive  
6 glycemic targets for DM management in the context of palliative care are usually suggested,  
7 recommendations are mainly based on expert opinion. Indeed, there is a lack of relevant evidence  
8 particularly from randomized clinical trials that guides DM management in the context of palliative  
9 care. Even the opinions of Diabetologists and Oncologists were different dealing with diabetes  
10 care in people with cancer [14]. To the best of our knowledge, the most resourceful nutritional  
11 approach, oral and injectable (non-insulin) agents, types of insulin or insulin regimens, are still  
12 unknown to manage DM in the palliative context. Therefore, the DM management in these  
13 patients remains a challenge.

14  
15  
16 Palliative medicine manages the whole person, providing not only the relief from pain, depression  
17 and other distressing symptoms at any stage of the disease but also treats joint chronic diseases.  
18 As such, the appropriate treatment of hyperglycemia-related symptoms and DM-related acute  
19 complications that can contribute to worsening patients' general condition and QOL, particularly  
20 acute complications, which commonly lead to hospital admissions and additional consequences.  
21 Comfort, patient preferences, evaluation of oral intake, and preservation of QOL are of particular  
22 importance in palliative medicine and interdisciplinary team care and early referral to relevant  
23 clinicians are essential.

### 24 25 26 **Objectives**

27  
28  
29 This systematic review was developed after a multidisciplinary discussion between the authors of  
30 shared doubts and concerns regarding DM management in the context of palliative care. The aim  
31 of our systematic review is to identify the best management of DM in order to reduce important  
32 DM-related symptoms (polyuria, polydipsia, and polyphagia) and acute complications  
33 (hypoglycemia, hyperglycemic hyperosmolar state, and diabetic ketoacidosis) in patients  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 receiving palliative care. The results of this systematic review may guide practices to improve  
4 patient care and be a stimulus for additional studies regarding DM management in palliative care.  
5  
6  
7

## 8 9 **METHODS AND ANALYSIS**

10  
11 The present protocol followed the preferred reporting items for systematic reviews and meta-  
12 analysis protocols (PRISMA-P) that was defined in 2015 [15], subsequent to the PRISMA  
13 Statement. The protocol is registered online on the international prospective register of systematic  
14 reviews, PROSPERO: CRD42018115772.  
15  
16  
17  
18

### 19 **Eligibility criteria**

20  
21 The population, intervention, comparator and outcomes as described by the PRISMA Statement  
22 [16] are reported below.  
23  
24  
25

#### 26 **Type of population**

27  
28 We will include studies of diabetic adult ( $\geq 18$  years old) patients receiving palliative care. We will  
29 exclude studies of pediatric population, those who do not have DM, and the patients who are not  
30 in palliative care.  
31  
32  
33

#### 34 **Type of intervention**

35  
36 We will include primary studies reporting the intervention: management of DM. Details regarding  
37 diet, oral and injectable (non-insulin) glucose-lowering drugs, insulin regimens and blood glucose  
38 monitoring strategies will be evaluated. Different approaches according to the etiology of DM,  
39 duration of DM, stage of palliative disease (stable, unstable, deteriorating, terminal) will also be  
40 assessed.  
41  
42  
43  
44  
45  
46

#### 47 **Type of comparator**

48  
49 The comparator item will be the different treatments and/or approaches used to manage DM in  
50 patients receiving palliative care.  
51  
52

#### 53 **Type of outcome**

1  
2  
3 We have defined primary outcomes as specific measures of the presence of symptoms (polyuria,  
4 polydipsia, and polyphagia) and acute complications of DM (hypoglycemia, hyperglycemic  
5 hyperosmolar state, and diabetic ketoacidosis) in order to make a feasible comparison of the  
6 different types of DM management approaches. If data exists, we will also report the secondary  
7 outcomes: hospital admissions due to DM-related complications, deaths due to DM-related  
8 complications, health-related QOL (objective measures), advanced care planning, documented  
9 advance care plans and glycemic control measured by HbA1c or average glycemia.  
10  
11  
12  
13  
14  
15  
16  
17

### 18 Type of studies

19  
20 We will include studies of any design regarding DM treatment and management in adult patients  
21 receiving palliative care. We will include only studies with a minimum of 10 participants. We will  
22 exclude editorials, comments, case reports, and other reviews and studies before 1990 (year of  
23 the first formal definition of palliative care by the World Health Organization).  
24  
25  
26  
27

### 28 Information sources

29  
30 We will search the following electronic bibliographic databases: Ovid MEDLINE, Embase,  
31 PubMed Central, Web of Sciences, Cochrane Central Register of Controlled Trials (CENTRAL),  
32 Cochrane Database of Systematic Reviews (CDSR), Scopus, Cumulative Index to Nursing and  
33 Allied Health Literature (CINAHL). Grey literature will be searched using the Grey Literature  
34 Report and Open Grey databases.  
35  
36  
37  
38  
39  
40

### 41 Search strategy

42  
43 The search will be conducted as soon as this protocol is published. Core health bibliographic  
44 databases will be searched from January 1990 to May 2019.  
45  
46

47 The search strategy will include terms defined in accordance to population, intervention,  
48 comparator and outcomes as described above. The search strategy will be defined for Pubmed  
49 and then will be adapted for use with other bibliographic databases. No filters or limitations will be  
50 applied to the search strategy to ensure retrieval of pre-indexed materials. Only studies in English,  
51 Spanish and Portuguese will be included. Grey literature will include unpublished conference  
52  
53  
54  
55  
56  
57

1  
2  
3 proceedings or abstracts from relevant speciality conferences. Reference lists of previous reviews  
4 and of included studies will also be screened looking for potentially eligible studies. The full search  
5 strategy for each database is available in the supplementary material.  
6  
7  
8

## 9 **Study records**

### 10 Data management

11  
12 We will apply the inclusion and exclusion criteria outlined above to the potentially eligible studies  
13 retrieved using our search strategy. For studies selection, we will use Covidence – Better  
14 Systematic Review Management [17]. All the records identified in the search strategy will be  
15 downloaded as Research Information Systems (RIS) files and uploaded to EndNote (as a security  
16 copy) and to Covidence.  
17  
18  
19

### 20 Selection process

21  
22 Covidence will automatically identify and exclude the duplicates. After obtaining the final  
23 potentially eligible articles to include in this systematic review, titles and abstracts will be screened  
24 by two independent reviewers considering the inclusion and exclusion criteria outlined. Based on  
25 these criteria, the independent reviewers will accept or reject studies. Each study will be voted by  
26 the two authors. Conflicts will be solved by a third author not involved in screening the papers.  
27  
28 Potentially eligible studies will be uploaded into Covidence for full-text screening. Similarly, this  
29 process will be done by two independent reviewers. The same procedure will be applied and any  
30 disagreement between them will be resolved by a third reviewer.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 Data collection process

44  
45 Relevant data will be extracted into a predefined data extraction sheet. This data extraction sheet  
46 will be designed for the purpose of this study and will be piloted per the authors responsible for  
47 the data extraction with a minimum of 5 studies.  
48  
49

50  
51 Seven authors will extract data from potentially eligible studies. Each study will be double-  
52 reviewed: one author will extract the data and a second author will independently check the data  
53 extraction forms for accuracy and detail. Discrepancies between the authors will be solved by  
54  
55  
56  
57

1  
2  
3 another author and discussed until reaching consensus. Data extraction will also be done using  
4 the software Covidence. Authors of eligible studies will be contacted by email to provide missing  
5 or additional data.  
6  
7  
8

#### 9 Data items

10  
11 The data extraction sheet will contain information regarding study setting, study population,  
12 participant's characteristics, study methodology, life-threatening illness related data (etiology of  
13 disease, stage of palliative care), details of DM (type and duration of DM, usual treatment namely  
14 class of oral or injectable (non-insulin) glucose-lowering drugs, type of insulin, insulin regimen),  
15 type of DM management used in the palliative care (blood glucose monitoring strategies, diet,  
16 oral glucose-lowering medicines, type of insulin and insulin regimen such as sliding scale insulin  
17 or scheduled insulin therapy with only basal insulin treatment or basal bolus insulin regimen) [18]  
18 and information for assessment of the risk of bias. The frequency of DM-related symptoms  
19 (polyuria, polydipsia, and polyphagia) and DM-related acute complications (hypoglycemia,  
20 hyperglycemic hyperosmolar state, and diabetic ketoacidosis) will be extracted and evaluated  
21 according to different DM approaches, such as insulin treatment alone or combined with other  
22 glucose lowering-drugs. Hospital admission and deaths due to DM-related complications, QOL,  
23 HbA1c and average glycemia will also be extracted where available.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

#### 39 Outcomes and prioritization

40  
41 All the variables will be extracted as string variables. As mentioned in the type of outcomes  
42 section, we will extract all the data available regardless if it is a main or additional outcome. We  
43 will not apply prioritization schemes as meta-analysis will not be performed.  
44  
45  
46

#### 47 Risk of bias in individual studies

48  
49 Two independent reviewers will assess the risk of bias and quality evidence of the eligible studies  
50 using the Study Quality Assessment Tools of the *National Institutes of Health* [19]. Disagreements  
51 between the review authors over the risk of bias will be resolved by a third author and discussed  
52 until reaching consensus. Any discrepancies or unusual patterns will be checked with the study  
53  
54  
55  
56  
57  
58  
59  
60

investigator, although we will not exclude studies based on their quality report, we will describe the quality of the included studies.

#### Data synthesis

The results will be summarized in tables containing the year, country, population, type of treatment and/or approach for DM, and the outcomes. The comparison between these variables will be further described. We will write a descriptive synthesis of the findings from the included studies, structured from the patients' characteristics, type of diabetes management, details of the disease for which the patient was referred to palliative care, and acute complications and symptoms of DM. If data exists, we will provide summaries of intervention effects for each study.

#### Analysis of subgroups or subsets

If there is enough data, we will perform sub-group analysis by age groups, sex, etiology of the disease requiring palliative care, stage of palliative care, type of DM, different settings (acute or primary care sector, professional or family care), and study design.

#### Patient and public involvement

Patients and the public will not be involved in this study.

**Ethics and dissemination:** The systematic review methodology does not require ethics approval due to the nature of the study design. The results of the systematic review will be published in a peer-reviewed journal and will be publically available. It will also be disseminated electronically and in printed versions.

**Authors' contributions:** RBS is the primary author for the study. RBS and MSP conceived, designed the study and drafted the protocol. MSP is the corresponding author. MSP and LÖ performed the full search strategy for each database. LÖ provided feedback on study protocol design and critically revised earlier versions of the manuscript. BA, VSA, RB, VG, MJMR and DC critically revised earlier drafts of the manuscript for intellectual content. All the authors read and approved the final manuscript.



**Funding statement:** This study did not require any funding.

**Competing interests:** None.

**Data sharing:** No additional data available.

**Patient consent:** Not required per the study design.

## REFERENCES

- 1 World Health Organization. WHO | WHO Definition of Palliative Care. WHO. 2012.<http://www.who.int/cancer/palliative/definition/en/> (accessed 14 Nov 2018).
- 2 World Health Organization. Palliative Care: symptom management and end-of-life care. Integrated Management of Adolescents and Adult Illness - Interim Guidelines for first level facility health workers. 2004. <https://www.who.int/3by5/publications/documents/en/genericpalliativecare082004.pdf> (accessed 10 Mar 2019).
- 3 World Health Organization. WHO Fact Sheets on Palliative Care. <http://www.who.int/news-room/fact-sheets/detail/palliative-care> (accessed 14 Nov 2018).
- 4 Surveillance Research Program NCI. SEER\*Explorer: An interactive website for SEER cancer statistics. <https://seer.cancer.gov/explorer/> (accessed 14 Nov 2018).
- 5 Johnston GM, Lethbridge L, Talbot P, *et al*. Identifying persons with diabetes who could benefit from a palliative approach to care. *Can J diabetes* 2015;**39**:29–35. doi:10.1016/j.jcjd.2014.01.009
- 6 The World Hospice Palliative Care Association. WHO Global Atlas on Palliative Care At the End of Life. <http://www.thewhpc.org/resources/global-atlas-on-end-of-life-care> (accessed 14 Nov 2018).
- 7 Dunning T, Martin P. Palliative and end of life care of people with diabetes: Issues, challenges and strategies. *Diabetes Res Clin Pr* 2018;**143**:454–63. doi:DOI: 10.1016/j.diabres.2017.09.018
- 8 American Diabetes Association AD. 12. Older Adults: Standards of Medical Care in Diabetes-2019. *Diabetes Care* 2019;**42**:S139–47. doi:10.2337/dc19-S012
- 9 Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type 2 diabetes in

- 1  
2  
3 older people. *Diabetes Res Clin Pract* 2014;**103**:538–40.  
4 doi:10.1016/j.diabres.2014.03.005  
5  
6  
7 10 Davies MJ, D'Alessio DA, Fradkin J, *et al.* Management of Hyperglycemia in Type 2  
8 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and  
9 the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018;**41**:2669–  
10 701. doi:10.2337/dci18-0033  
11  
12  
13  
14 11 Garber AJ, Abrahamson MJ, Barzilay JI, *et al.* Consensus statement by the American  
15 Association of Clinical Endocrinologists and American College of Endocrinology on the  
16 comprehensive type 2 diabetes management algorithm – 2018 Executive Summary.  
17 *Endocr Pract* 2018;**24**:91–120. doi:10.4158/CS-2017-0153  
18  
19  
20  
21 12 Ferrari P, Giardini A, Negri E, *et al.* Managing people with diabetes during the cancer  
22 palliation in the era of simultaneous care. *Diabetes Res Clin Pr* 2018;**143**:443–53. doi:DOI:  
23 10.1016/j.diabres.2017.12.010.  
24  
25  
26  
27 13 American Diabetes Association AD. 6. Glycemic Targets: Standards of Medical Care in  
28 Diabetes-2019. *Diabetes Care* 2019;**42**:S61–70. doi:10.2337/dc19-S006  
29  
30  
31 14 Clemente G, Giorgini M, Mancini M, *et al.* Diabetologists and Oncologists attitudes towards  
32 treating diabetes in the oncologic patient: Insights from an exploratory survey. *Diabetes*  
33 *Res Clin Pract* 2018;**143**:420–7. doi:10.1016/J.DIABRES.2018.02.044  
34  
35  
36 15 Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic review and  
37 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*  
38 2015;**350**:g7647. doi:10.1136/BMJ.G7647  
39  
40  
41 16 Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA Statement for Reporting Systematic  
42 Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions:  
43 Explanation and Elaboration. *PLoS Med* 2009;**6**:e1000100.  
44 doi:10.1371/journal.pmed.1000100  
45  
46  
47  
48 17 Babineau J. Product Review: Covidence (Systematic Review Software). *J Can Heal Libr*  
49 *Assoc / J l'Association des bibliothèques la santé du Canada* 2014;**35**:68. doi:10.5596/c14-  
50 016  
51  
52  
53 18 Umpierrez GE, Hellman R, Korytkowski MT, *et al.* Management of Hyperglycemia in  
54 Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice  
55  
56  
57  
58  
59  
60

1  
2  
3 Guideline. *J Clin Endocrinol Metab* 2012;**97**:16–38. doi:10.1210/jc.2011-2098  
4

- 5 19 National Heart Lung and Blood Institute. Study Quality Assessment Tools - NHLBI, NIH.  
6 2016.<https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> (accessed 21  
7 Nov 2018).  
8  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Diabetes-related symptoms, acute complications and**  
4 **management of diabetes mellitus in palliative care: a**  
5 **systematic review.**  
6  
7  
8  
9

10  
11 Search strategy for **PubMed**:  
12  
13

14 ((((((((((diabetes mellitus[MeSH Terms]) OR diabet\*[Title/Abstract])) OR  
15 T1DM[Title/Abstract]) OR T2DM[Title/Abstract]) OR NIDDM[Title/Abstract]) OR  
16 IDDM[Title/Abstract]) OR "glucose lowering medicine\*[Title/Abstract]) OR  
17 hyperglycemia[MeSH Major Topic]) OR hyperglycemia\*[Title/Abstract]) AND  
18 ((((((((((palliative care[MeSH Major Topic]) OR terminal care[MeSH Major Topic]) OR  
19 palliative[Title/Abstract]) OR "terminal care"[Title/Abstract]) OR "supportive  
20 care"[Title/Abstract]) OR "Terminal patient" [Title/Abstract]) OR "terminal patients"  
21 [Title/Abstract]) OR "End of Life Care"[Title/Abstract]) OR "Terminal  
22 Phase"[Title/Abstract])  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60